BioVersys to Present at H.C. Wainwright 28th Annual Global Investment Conference

BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company dedicated to developing novel antibacterial products for serious infections caused by multidrug-resistant (MDR) bacteria, has announced its participation in the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The event, scheduled from September 14 to 16, 2026, in New York City, will feature a corporate overview by BioVersys' management, underscoring the company's strategic initiatives and recent advancements in its pipeline.

During the conference, BioVersys' Chief Financial Officer, Hernan Levett, will deliver a live presentation on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room (4th Floor) of the Lotte New York Palace. Additionally, Chief Executive Officer, Dr. Marc Gitzinger, will provide an on-demand presentation, which will be available for replay for 90 days starting September 11, 2026. The webcast can be accessed through the H.C. Wainwright platform or via the BioVersys website in the investor section. Both executives will be available for one-on-one meetings with registered attendees during the conference, offering an opportunity for deeper engagement with investors.

This participation comes at a critical time for BioVersys, which is leveraging its proprietary technology platforms, TRIC and Ansamycin Chemistry, to develop treatments that overcome resistance mechanisms and target the pathogenesis of harmful bacteria. The company's most advanced programs address nosocomial infections caused by Acinetobacter baumannii (BV100, currently in Phase 3) and tuberculosis (alpibectir, in Phase 2, in collaboration with GlaxoSmithKline and a consortium from the University of Lille). These efforts highlight BioVersys' commitment to tackling the growing global threat of antimicrobial resistance, a public health crisis that requires innovative solutions.

The conference presents a significant opportunity for BioVersys to communicate its value proposition to the investment community, particularly as the company advances its lead asset BV100 through late-stage clinical development. With the World Health Organization listing antimicrobial resistance as one of the top global public health threats, BioVersys' focus on MDR bacteria positions it as a key player in addressing this unmet medical need. By presenting at such a prominent investment conference, BioVersys aims to attract potential partners and investors who recognize the urgent need for new antibacterial therapies.